Viking Therapeutics, Inc (VKTX) News
Latest headlines that mention VKTX, newest first · each headline opens the original publisher
- Last price
- $27.73
- Day change
- -2.84%
- Next earnings
- 2026-10-28
VKTX headlines
last 30 daysThe weight loss drug company continues to make progress, but its share price is bouncing around with events.
There could be more catalysts for the biotech over the next 18 months.
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.
The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.
The company continues to make good progress with its key obesity treatment drug, VK2735.
The biotech player could eventually rival big pharma companies.
It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.
Viking stock catapulted Tuesday on "stellar" test results for its weight-loss shot, sending shares of rival Novo lower. The post Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls. appeared first on Investor's Business Daily .
Also mentioned with VKTX
30dHeadlines that tag both tickers
VKTX news alerts
Get an alert by email or push when a new headline mentions VKTX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.